Año 2021 / Volumen 113 / Número 8
Original
Long-term outcomes and clinical impact of anti-HLA donor-specific antibodies (DSA) after liver transplantation: a prospective study in a pilot cohort

557-562

DOI: 10.17235/reed.2020.7337/2020

Aranzazu Caballero Marcos, Raquel Díaz Ruiz, Mario Romero Cristóbal, Ainhoa Fernández Yunquera, Fernando Díaz-Fontenla, Leticia Pérez Carazo, María Isabel Peligros Gómez, José Luis Vicario Moreno, Magdalena Salcedo Plaza, Rafael Bañares Cañizares,

Resumen
Introduction: the presence of donor-specific antibodies (DSA) is thought to affect survival of the allograft and patient after liver transplantation (LT). However, their significance is not well understood. Patients and methods: a prospective study was performed of 32 adult patients who underwent LT in 2011 to analyze the existence of DSA, associated risk factors and medium-term impact. Immunological determinations were performed immediately before LT and at three, six, 12 months and five years after LT. Results: eight patients (24.2 %) presented pre-formed DSA. However, titers were negative in all patients five years after LT and there were no associated events. Eight out of 24 patients (33.3 %) developed de novo DSA. After five years, only two remained positive; both were class II with high mean fluorescence intensity (MFI) values at diagnosis (over 15,000). No association was found between the development of DSA and the risk of rejection, graft loss or death. However, an increase in liver stiffness values was observed in patients with persistent DSA, and focal sinusoidal deposition of C4d and moderate liver fibrosis were reported. Conclusion: the incidence of DSA is high after LT. In addition, the persistence of de novo DSA could be associated with silent liver fibrosis with a potential impact on graft outcomes.
Share Button
Nuevo comentario
Comentarios
No hay comentarios para este artículo.
Bibliografía
1. Ogura K, Koyama H, Takemoto S, et al. Significance of a positive crossmatch on outcome in human liver transplantation. Transplant Proc. 1992 Aug;24(4):1465.
2. Ogura K, Terasaki PI, Koyama H, et al. High one-month liver graft failure rates in flow cytometry crossmatch-positive recipients. Clin Transpl. 1994;8(2 Pt 1):111–5.
3. Takaya S, Duquesnoy R, Iwaki Y, et al. Positive crossmatch in primary human liver allografts under cyclosporine or FK 506 therapy. Transplant Proc. 1991 Feb;23(1 Pt 1):396–9.
4. Iacob S, Cicinnati VR, Lindemann M, et al. Donor-Specific Anti-HLA Antibodies and Endothelial C4d Deposition-Association with Chronic Liver Allograft Failure. Transplantation. 2015;99(9):1869–75.
5. Taner T, Gandhi MJ, Sanderson SO, et al. Prevalence, Course and Impact of HLA Donor-Specific Antibodies in Liver Transplantation in the First Year. Am J Transplant. 2012 Jun;12(6):1504–10.
6. Kozlowski T, Rubinas T, Nickeleit V, et al. Liver allograft antibody-mediated rejection with demonstration of sinusoidal C4d staining and circulating donor-specific antibodies. Liver Transplant. 2011;17(4):357–68.
7. O’Leary JG, Klintmalm GB. Impact of donor-specific antibodies on results of liver transplantation. Vol. 18, Current Opinion in Organ Transplantation. 2013. p. 279–84.
8. Willuweit K, Heinold A, Rashidi-Alavijeh J, et al. Immunosuppression with mTOR inhibitors prevents the development of donor-specific antibodies after liver transplant. Clin Transplant. 2017;31(6).
9. Jordan SC, Vo AA. Donor-specific antibodies in allograft recipients: Etiology, impact and therapeutic approaches. Vol. 19, Current Opinion in Organ Transplantation. 2014. p. 591–7.
10. Kaneku H, O’Leary JG, Banuelos N, et al. De novo donor-specific HLA antibodies decrease patient and graft survival in liver transplant recipients. Am J Transplant. 2013;13(6):1541–8.
11. Del Bello A, Congy-Jolivet N, Danjoux M, et al. De novo donor-specific anti-HLA antibodies mediated rejection in liver-transplant patients. Transpl Int. 2015;
12. Vandevoorde K, Ducreux S, Bosch A, et al. Prevalence, Risk Factors, and Impact of Donor-Specific Alloantibodies After Adult Liver Transplantation. Liver Transplant. 2018;
13. Tisone G. Post-transplant donor-specific antibody production and graft outcome in kidney transplantation: results of sixteen-year monitoring by flow cytometry. Clin Transpl. 2006. p. 323–36.
14. Lachmann N, Terasaki PI, Schönemann C, et al. Donor-specific HLA antibodies in chronic renal allograft rejection: a prospective trial with a four-year follow-up. Clin Transpl. 2006;171–99.
15. Del Bello A, Congy-Jolivet N, Muscari F, et al. Prevalence, incidence and risk factors for donor-specific anti-HLA antibodies in maintenance liver transplant patients. Am J Transplant. 2014;14(4):867–75.
16. Fontana M, Moradpour D, Aubert V, et al. Prevalence of anti-HLA antibodies after liver transplantation. Vol. 23, Transplant International. 2010. p. 858–9.
17. Ohe H, Uchida Y, Yoshizawa A, et al. Association of anti-human leukocyte antigen and anti-angiotensin II type 1 receptor antibodies with liver allograft fibrosis after immunosuppression withdrawal. Transplantation. 2014;98(10):1105–11.
18. O’Leary JG, Smith C, Cai J, et al. Chronic AMR in liver Transplant: Validation of the 1-Year cAMR score’s ability to determine long-term outcome. Transplantation. 2017;101(9):2062–70.
19. O’Leary JG, Cai J, Freeman R, et al. Proposed Diagnostic Criteria for Chronic Antibody-Mediated Rejection in Liver Allografts. Am J Transplant. 2016;16(2):603–14.
20. Miyagawa-Hayashino A, Yoshizawa A, et al. Progressive graft fibrosis and donor-specific human leukocyte antigen antibodies in pediatric late liver allografts. Liver Transplant. 2012;18(11):1333–42.
21. Kaneku H, O’Leary JG, Taniguchi M, et al. Donor-specific human leukocyte antigen antibodies of the immunoglobulin G3 subclass are associated with Chronic rejection and graft loss after liver transplantation. Liver Transplant. 2012;18(8):984–92.
Artículos relacionados

Imagen en Patología Digestiva

Síndrome de encefalopatía posterior reversible (PRES) en el postrasplante hepático

DOI: 10.17235/reed.2022.8694/2022

Carta

Neurotoxicidad por ertapenem

DOI: 10.17235/reed.2021.8469/2021

Revisión

La fragilidad física en el contexto del trasplante hepático

DOI: 10.17235/reed.2020.7448/2020

Carta

Manejo de los aneurismas de la arteria hepática

DOI: 10.17235/reed.2020.7219/2020

Imagen en Patología Digestiva

Hemangioendotelioma epitelioide como causa infrecuente de tumor hepático

DOI: 10.17235/reed.2020.7127/2020

Carta al Editor

Post-transplant lymphoproliferative disease after liver transplantation

DOI: 10.17235/reed.2017.5387/2017

Original

Síndrome linfoproliferativo en el trasplante hepático

DOI: 10.17235/reed.2017.4228/2016

Instrucciones para citar
Caballero Marcos A, Díaz Ruiz R, Romero Cristóbal M, Fernández Yunquera A, Díaz-Fontenla F, Pérez Carazo L, et all. Long-term outcomes and clinical impact of anti-HLA donor-specific antibodies (DSA) after liver transplantation: a prospective study in a pilot cohort. 7337/2020


Descargar en un gestor de citas

Descargue la cita de este artículo haciendo clic en uno de los siguientes gestores de citas:

Métrica
Este artículo ha sido visitado 1541 veces.
Este artículo ha sido descargado 181 veces.

Estadísticas de Dimensions


Estadísticas de Plum Analytics

Ficha Técnica

Recibido: 12/06/2020

Aceptado: 28/08/2020

Prepublicado: 27/11/2020

Publicado: 28/07/2021

Tiempo de revisión del artículo: 74 días

Tiempo de prepublicación: 168 días

Tiempo de edición del artículo: 411 días


Compartir
Este artículo aun no tiene valoraciones.
Valoración del lector:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
La REED es el órgano oficial de la Sociedad Española de Patología Digestiva, la SociedadEspañola de Endoscopia Digestiva y la Asociación Española de Ecografía Digestiva
Política de cookies Política de Privacidad Aviso Legal © Copyright 2023 y Creative Commons. Revista Española de Enfermedades Digestivas